Market Signal Briefing

XRP Faces Bearish Cross Risk, Sinks 5% Even as ETFs Move FurtherThe token's ability to defend the $2.39–$2.41 range will determine if it rebounds or faces further declines.Updated Nov 12, 2025, 5:20 a.m. Published Nov 12, 2025, 5:20 a.m.

(CoinDesk Data)

What to know: XRP fell 5.1% to $2.41 as technical selloffs and whale transfers increased market uncertainty.Trading volume spiked 46% above daily averages, with sellers breaking through key support levels.The token's ability to defend the $2.39–$2.41 range will determine if it rebounds or faces further declines.The Ripple-linked token broke through multiple technical floors while whale transfers injected fresh uncertainty into an already fragile market structure.

News BackgroundXRP plunged 5.1% to $2.41 during Tuesday’s session, sliding from $2.54 as selling pressure overwhelmed key support zones. The move unfolded without direct macro catalysts, instead reflecting a technical-driven selloff amplified by volume expansion and large-scale token movements across major wallets.Tennessee-based Canary filed an 8-A form on Monday, a U.S. Securities and Exchange requirement for companies registering securities. The Canary XRP ETF would track the spot price of the fourth largest digital asset by market capitalization.Whale activity compounded volatility, with over $1 billion in XRP moved between Ripple-linked custodial addresses. While on-chain data suggested the transfers were internal rather than exchange-related, the timing created renewed uncertainty during a period of heightened technical fragility.Price Action SummaryThe decline stabilized near $2.39–$2.41 as short-term buyers stepped in to absorb selling pressure. The token rebounded modestly from $2.408 lows, climbing to $2.418 during the overnight session. Hourly data showed a 4.5% bounce off session bottoms, with volume topping 1.1 million at 02:01 UTC, suggesting opportunistic accumulation at discounted levels.Despite the brief recovery, XRP remains technically constrained. Consecutive lower highs from the $2.54 peak reflect persistent distribution patterns. Failure to regain $2.47 or reclaim broken support at $2.43 leaves the broader setup vulnerable to further downside tests.Technical AnalysisThe broader structure tilts bearish as momentum indicators flag deterioration across mid-term timeframes. The developing Death Cross pattern—where the 50-day moving average converges below the 200-day—adds to short-term caution. RSI readings hover near oversold territory, hinting at possible near-term relief, but trend confirmation requires stronger participation from institutional buyers.The 38.2% Fibonacci retracement near $2.42 defines immediate resistance, while any recovery above $2.47 could reestablish short-term balance. Beneath $2.35, however, the risk of an extended decline toward the $2.20–$2.25 zone increases sharply.What Traders Should KnowXRP’s ability to defend the $2.39–$2.41 band will determine whether the move evolves into a technical rebound or extends into deeper correction territory.The lack of panic volume on the final leg lower suggests controlled profit-taking rather than capitulation, though whale activity remains a wild card for sentiment.Institutional traders continue to monitor Ripple-related on-chain flows as potential leading indicators for liquidity-driven shifts. With broader crypto sentiment mixed, the next decisive move hinges on whether XRP can reclaim $2.47—its near-term pivot point separating stabilization from sustained downside.More For You

Inside Zcash: Encrypted Money at Planetary Scale

Nov 3, 2025

A deep dive into Zcash's zero-knowledge architecture, shielded transaction growth, and its path to becoming encrypted Bitcoin at scale.

What to know:

In 2025, Zcash evolved from niche privacy tech into a functioning encrypted-money network:

Shielded adoption surged, with 20–25% of circulating ZEC now held in encrypted addresses and 30% of transactions involving the shielded pool.The Zashi wallet made shielded transfers the default, pushing privacy from optional to standard practice.Project Tachyon, led by Sean Bowe, aims to boost throughput to thousands of private transactions per second.Zcash surpassed Monero in market share, becoming the largest privacy-focused cryptocurrency by capitalization.View Full Report

More For You

Coinbase Ends Acquisition Talks for U.K.-Based BVNK: Fortune

40 minutes ago

The negotiations, which began earlier this year and progressed to an exclusivity agreement in October, were expected to value BVNK between $1.5 billion and $2.5 billion.

What to know:

Coinbase has ended acquisition talks with the U.K.-based stablecoin startup BVNK, which could have been a major deal in digital payments.The decision to halt the talks was confirmed by a Coinbase spokesperson, but no reasons were provided.The acquisition of BVNK would have enhanced Coinbase's position in cross-border payments and merchant services.Read full story

Top Stories

A recent report by Wintermute suggests that current crypto market conditions do not favor an immediate altcoin season. Instead, the analysis indicates that bitcoin is likely to outperform altcoins in the near term.

November 12, 2025 05:24:08 UTC Canary Capital CEO Predicts XRP ETF Could Outperform Solana Steven McClurg, CEO of Canary Capital, predicts that the upcoming XRP spot ETF could outperform Solana's gains, potentially doubling its impact. The ETF is set to launch Thursday, following the final regulatory approval from the Nasdaq.

Sonic Labs now wants to reward users based on real activity on the network and long-term value. CEO Mitchell Demeter stated that the company will focus on steady growth, token burns, and fair rewards for developers, rather than pursuing quick market gains.

Demeter posted an article on X that accurately highlights this plan, stating that Sonic Labs will connect real network use, its token value, and developer rewards through updates to its system and business model. 

Sonic Labs wants to build real value on its network
CEO Mitchell Demeter said Sonic already has a fast and reliable token system, and the company wants everyone to benefit from it. Instead of chasing short-term market reactions, the plan will make sure every transaction, project, and partnership rewards builders and users in the long run.

The company will eliminate 90% of all transaction fees and allocate the remaining 10% to validators, making the remaining tokens rarer and more valuable over time. The more people build, use, and support the network, the more rewards they receive, creating a loop where participation generates value that grows with the network.

Demeter also explained that tokenholders and other participants will be able to vote on decisions about rewards, token burns, and other important rules. The system will be fair and transparent, ensuring that people who use and support the network have a say in its growth.

Sonic Labs will also ensure fair reward distribution to validators and control token provisioning, allowing the network to be sustained for a longer period.

The company will also introduce selected Ethereum Improvement Proposals (EIPs) and launch its own Sonic Improvement Proposals (SIPs) to enhance the network’s utility for real-world projects and users. Developers will receive a system that rewards them for building and connecting new applications to other networks. Sonic wants more to come on board to increase the level of activity, creating more rewards and value for everyone involved.

The rewards system boosts Sonic’s expansion, education, and engagement by institutions
Sonic Labs plans to open an office in New York City, positioning it as the headquarters for its operations and partnerships. The company aims to showcase its true value to banks and investors, and the new office will enable it to expand in areas such as marketing, communications, and sales, thereby educating the broader public. 

Sonic’s media and learning platform, GMSonic, began as a podcast, but the company has since expanded it into a comprehensive platform that shares educational content with its community members. The firm aims to educate new developers on how to utilize Sonic, recognize builders for their contributions, and inform community members about all the activities within the ecosystem. 

Sonic will also continue hosting its Sonic Global Summit and participating in other major conferences to educate people and encourage them to join its ecosystem, allowing them to benefit as well. The company aims to establish a network that fosters learning and collaboration between builders and users. In return, the platform will become stronger in the long term, and everyone will benefit from their participation.

CEO Mitchell Demeter stated that the company has a healthy treasury, a substantial pool of liquidity, and the necessary resources to expand its team and plans. He called the approach “speed with purpose,” and said the goal of the company is to build a system where everyone has a reason to participate, help the network grow, and benefit from its success. 

If you're reading this, you’re already ahead. Stay there with our newsletter.

TLDR:

SoFi becomes the first nationally‑chartered U.S. bank to enable retail crypto trading.
Launch covers major tokens including Bitcoin, Ethereum and Solana under one platform.
Regulatory clarity from the OCC in 2025 freed banks to advance crypto services.
SoFi’s roadmap includes stablecoin issuance and crypto‑based infrastructure extensions.

Retail customers at SoFi Technologies, Inc. (“SoFi”) can now buy, sell and hold crypto. This makes the firm the first U.S. nationally chartered bank to offer direct crypto trading. The product launch follows regulators granting clearer guidance to banks on digital assets. 

According to CEO Anthony Noto, the offering is live for retail members now, with institutional access coming soon. The move arrives as crypto adoption among consumers and institutions grows despite persistent market volatility.

SoFi Crypto Trading: What’s on Offer and Why It Matters
SoFi’s trading product allows retail users to access dozens of tokens, including Bitcoin, Ethereum and Solana, according to Reuters. 

Noto stated that the bank’s national charter and regulatory clarity from the Office of the Comptroller of the Currency (OCC) give SoFi what he described as “the best license a company can have” for crypto and blockchain services.

The product phases in initially for retail members with a wait‑list system in place. Social posts by Noto confirmed the live rollout of crypto for consumers at the bank. 

The offering positions SoFi as an institutional player preparing to bring crypto to its broader lending, stablecoin, and infrastructure roadmap. This includes a planned U.S. dollar–pegged stablecoin and crypto‑based lending products.

The timing aligns with a broader trend of banks entering digital‑asset services now that regulators are issuing clearer guidance. As analysts note, demand remains steady among clients seeking crypto access despite price fluctuations.

Regulatory Shift and Strategic Implications for Crypto Banking
Until recently, U.S. banks largely steered clear of crypto due to uncertain regulatory status. 

In spring 2025, the OCC issued guidance permitting banks with the right charter to engage in crypto and blockchain activities. Noto cited this development as a key enabler for SoFi’s launch.

SoFi’s move may influence other banks and traditional financial firms to accelerate digital‑asset offerings. The company’s prior exit from crypto services in 2023 was required during its bank charter process; its return now reflects a strategic pivot back into digital assets.

From a market standpoint, SoFi’s crypto launch could signal increasing mainstream access to digital assets through banking channels rather than crypto‑native platforms. The success of this product could shape how regulators and financial institutions view crypto integration across banking, payments and lending services.

VCI Global buys $100 million in OOB token; Tether becomes largest shareholder

Partner offers

The Block may may earn a commission if you use our partner offers, at no extra cost to you.

Quick Take
The Nasdaq-listed firm is acquiring $100 million worth of OOB tokens, the native token of Tether-backed crypto payment firm Oobit. 
Following the completion of the deal, Tether is expected to become the largest shareholder of VCI Global through its Oobit stake.
VCI Global, a Malaysia-based technology consulting services firm, plans to acquire $100 million worth of OOB tokens, the utility token of Tether-backed crypto payment firm Oobit.

Under the deal structure, VCI Global acquired $50 million worth of OOB tokens through restricted share issuance to the OOB Foundation, according to the company's Tuesday statement. It plans to purchase an additional $50 million in tokens on the secondary market following the token's public launch.

The Nasdaq-listed firm said that Tether is set to become its largest shareholder following the transaction.

"We are not simply completing a digital-asset transaction," said Moshe Schisser, Chairman of Oobit. "This combination presents tremendous potential to accelerate growth and expand the real-world utility of our ecosystem."

Following the $100 million transaction, VCI Global plans to establish a dedicated digital treasury division to oversee its crypto initiatives and integrate the OOB token's utility into its existing AI, fintech, and sovereign data platforms.

Token rebrandMeanwhile, the OOB token is currently undergoing major changes. Oobit is rebranding the token from its former name "OBT" and migrating the token from Ethereum to Solana this week. The rebranded token is scheduled to launch on Nov. 12.

OOB will power Oobit, which offers tap-to-pay crypto transaction services at merchant point-of-sale systems. Oobit is backed by a number of other investors including Solana co-founder Anatoly Yakovenko, CMCC Global and 468 Capital.

VCI Global is a diversified holding company that develops and scales cross-sector platforms that integrate technology with financial architecture to develop sovereign-ready digital ecosystems.

On Oct. 31, VCI Global announced a $5 million raise, where the company sold shares at $1.8 each to an institutional investor in a registered direct offering.

VCI Global's stock fell 26.55% to close at $1.3 on the Nasdaq on Tuesday, according to Yahoo Finance data. The stock has plummeted 65.79% over the past month.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2025 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

TAGS

AUTHOR Timmy Shen is an Asia editor for The Block. Previously, he wrote about crypto and Web3 for Forkast.News from Taiwan after spending more than three years in Beijing covering finance, entertainment business and current affairs at Caixin Global and Chinese tech at TechNode. His China-related reporting has also appeared in The Guardian. When he's not chasing headlines, you'll find him savoring hot pot and shabu shabu in a Taipei local haunt. Timmy holds an MS degree from Columbia University Graduate School of Journalism. Send tips to [email protected] or get in touch on X/Telegram @timmyhmshen. See More

WHO WE ARE The Block is a news provider that strives to be the first and final word on digital assets news, research, and data. +
Follow us on Google News
More by Timmy Shen

According to a recent report by Bloomberg, the cybersecurity arm of China has openly accused the US government of orchestrating the theft of approximately $13 billion in Bitcoin (BTC), adding tension to the ongoing cyber relations between the two nations.

China Alleges State-Level Operation
The incident in question revolves around the theft of 127,272 BTC from the LuBian Bitcoin mining pool in December 2020, constituting one of the most substantial crypto heists in history. 

The Chinese National Computer Virus Emergency Response Center suggests that this large-scale hack was likely a planned “state-level hacker operation” orchestrated by the US. 

The agency points to the discreet and delayed movement of the stolen Bitcoin as indicative of governmental involvement rather than typical criminal behavior.

The report further links the Bitcoin from LuBian, a former Bitcoin mining firm, to tokens seized by the US government, which authorities claim are linked to Chen Zhi, the chairman of the Cambodian conglomerate Prince Group. 

Chen Zhi had been accused by the US of participating in a wire-fraud conspiracy and running a money-laundering scheme in October. Notably, details on when and how the Bitcoin was confiscated by the US remain undisclosed.

The narrative put forth in the report suggests that the US government might have employed hacking tactics as early as 2020 to appropriate the 127,000 Bitcoin associated with Chen Zhi, characterizing the operation as an example of a “black eats black” maneuver orchestrated by a state-level hacking entity.

Bitcoin Forfeiture Fallout
Federal prosecutors involved in the Chen case have refrained from disclosing the methods used to gain control of the Bitcoin, following the Department of Justice’s civil forfeiture complaint seizing the 127,271 BTC, which stands as the most substantial forfeiture action undertaken by the US government.

Recent statements from the Chinese government have highlighted a growing trend of accusing the American government of engaging in hacking activities. 

Earlier this year, China asserted that the US exploited vulnerabilities in Microsoft Exchange servers to target Chinese companies. Just last month, China alleged that it possessed undeniable evidence of a US cyber attack on the National Time Service Center.

In response to the allegations, a lawyer representing Chen Zhi has filed a request for additional time in a US court to allow for tracing of the stolen BTC from LuBian. The attorney, Matthew L. Schwartz has criticized the government’s claims against Chen as being “seriously misguided.” 

Schwartz, who serves as counsel to Mr. Chen and the Prince Group, stated that they are collaborating with cryptocurrency experts to trace the Bitcoin seized over a year ago and stolen back in 2020. T

The daily chart shows BTC’s consolidation above the key $100,000 level. Source: BTCUSDT on TradingView.com
At the time of writing, BTC was trading at $102,550, recording losses of 3% in the 24-hour time frame. 

Featured image from DALL-E, chart from TradingView.com 

TLDR:

Injective EVM mainnet launches with Chainlink from day one.
Data Streams enable on-demand, verifiable data for latency-sensitive dApps.
DataLink targets institutional integration and real-world assets on-chain.
Commit-and-reveal mechanism reduces frontrunning in financial applications.

Injective has officially launched its EVM-compatible mainnet, opening a new chapter for developers and institutions. From day one, Chainlink Data Streams and DataLink have been fully integrated, providing critical infrastructure. 

The platform promises high-speed transactions and multi-VM capability for on-chain finance. Developers now have tools to build advanced, latency-sensitive decentralized applications securely and efficiently.

Chainlink Integration Powers Injective’s Next-Gen Blockchain
Chainlink services were available immediately as the Injective EVM mainnet went live, ensuring seamless adoption for builders. 

Data Streams use a pull-based architecture, letting decentralized apps retrieve verified data on-demand. This setup suits trading platforms and derivatives protocols requiring minimal latency. The system employs a commit-and-reveal process to reduce frontrunning risk for real-time financial applications.

DataLink extends this capability for institutional users, supporting secure data publication and bridging capital markets to the blockchain. It allows developers to incorporate real-world assets on-chain without compromising verification or integrity. 

By combining high-speed transactions with verified data feeds, Injective positions itself as a robust environment for decentralized finance. Integrating Chainlink from launch provides Injective developers immediate access to reliable oracle infrastructure.

Institutional-grade features like DataLink aim to attract trading firms, hedge funds, and capital market participants. Secure, verifiable data is crucial for scaling decentralized applications beyond retail users. 

With this launch, Injective highlights both speed and reliability as core pillars of its blockchain ecosystem. Chainlink’s real-time data solutions are expected to enhance application trustworthiness significantly.

Congratulations to @injective on its successful EVM mainnet launch.

Chainlink Data Streams and DataLink are now live on InjectiveEVM from Day 1, providing Injective developers with the infrastructure required to build highly reliable, next-gen applications. https://t.co/bATINqLB66

— Chainlink (@chainlink) November 11, 2025

Developer Tools and Real-Time Transaction Infrastructure
Injective’s MultiVM network allows multiple virtual machines to run simultaneously, optimizing computational efficiency. Developers can leverage the EVM compatibility to port existing Ethereum dApps without extensive reconfiguration. 

On-demand data access via Data Streams minimizes delays, enabling more sophisticated financial products. The combination of Chainlink oracles and multi-VM throughput supports high-frequency trading and other latency-sensitive operations.

Security is reinforced through on-chain verification, giving developers confidence in data authenticity. Real-world asset integration opens possibilities for tokenized securities and other regulated products. 

Injective’s infrastructure targets retail and institutional participants, emphasizing scalability and reliability. The integration could accelerate adoption by bridging DeFi and traditional finance.

The platform’s design also anticipates future scaling needs, with flexible oracle networks supporting additional data types. 

Data integrity and transparency are maintained even in high-volume trading scenarios. This first-day integration demonstrates a coordinated effort between Injective and Chainlink to provide a fully functional ecosystem. Such readiness could set a standard for upcoming EVM-compatible launches.

Bitcoin falls to $103,000 as the crypto market slides amid uncertainty over the Fed's rate cut. Ethereum drops 4.7%, Solana plunges 8.8%. Analysts eye the $100,000 support level.

Newton Gitonga2 min read

12 November 2025, 06:21 AM

Major cryptocurrencies experienced significant losses on Wednesday morning as investors sought to secure profits amid mounting questions about the Federal Reserve's upcoming monetary policy decision in December. Bitcoin dropped below $103,000, while other digital assets posted steeper declines.

Bitcoin traded at $103,222 after falling 3% over the previous 24 hours, according to market data. Ethereum declined 4.7% to reach $3,434. XRP recorded a 5.3% drop to $2.40, while Solana saw the sharpest fall among major tokens, sliding 8.85% to $154.76.

The leading cryptocurrency had briefly recovered from earlier monthly lows of approximately $101,500 to reach above $106,600 before the recent selloff began. Trading activity on Tuesday pushed prices below the $103,000 threshold to around $102,600.

Technical Weakness Triggers LiquidationsMarket analysts pointed to multiple factors behind the sudden reversal. Vincent Liu, Chief Investment Officer at Kronos Research, highlighted the role of profit-taking behavior among investors. Bitcoin struggled to break through the resistance at $107,000, prompting long position holders to exit their trades.

The failure to maintain momentum above key price levels led to cascading liquidations. Leveraged positions magnified the downward pressure as automated stop-loss orders were triggered across trading platforms. Liu noted that these forced sales accelerated the decline beyond what fundamental factors alone would suggest.

A brief uptick in cryptocurrency prices had followed the U.S. Senate's approval of legislation to reopen the government. The resolution of the prolonged shutdown initially boosted risk appetite among traders. However, the positive sentiment proved short-lived as technical factors reasserted themselves.

"The macro relief rally faded fast," Liu stated. He identified $100,000 as the next critical support level for Bitcoin. A breach of this psychological barrier could unleash additional selling pressure and increase market volatility.

Federal Reserve Decision Creates UncertaintyThe Federal Reserve's upcoming policy meeting has emerged as the primary catalyst for cryptocurrency market movements. Traders had initially expected another interest rate reduction in December. Lower rates typically benefit digital assets by reducing yields on traditional investments and encouraging capital flows into riskier assets.

Fed Chair Jerome Powell recently tempered expectations about a December rate cut. His comments suggested that policymakers remain cautious about further monetary easing despite earlier indications. The shift in messaging caught some market participants off guard.

New reporting revealed growing divisions within the Federal Reserve regarding the appropriate policy stance. Officials remain split on whether economic conditions warrant another reduction in borrowing costs at the December meeting. The lack of consensus has added to investor uncertainty.

The CME Group's FedWatch Tool currently shows a 66.9% probability of a rate cut at the Fed's December 9-10 meeting. While this represents a majority expectation, it reflects less certainty than markets typically prefer when positioning for major policy shifts.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

BitcoinEthereumXRP (Ripple) NewsLatest Solana (SOL) News Today

, /PRNewswire/ -- Tech Mahindra (NSE: TECHM), a leading global provider of technology consulting and digital solutions to enterprises across industries, today announced a licensing agreement with AT&T for its proprietary Automated Network Testing (ANT) and Open Tool platforms. These applications deliver an advanced platform designed to transform network testing and certification across Long Term Evolution (LTE), 5G Non-Standalone (NSA), and 5G Standalone (SA) domains.

Tech Mahindra will integrate the ANT and Open Tool into its suite of telecommunications solutions, which will empower Communication Service Providers (CSPs) to conduct network health checks, connectivity tests, and debugging with unprecedented speed and precision, ensuring a robust and reliable network for the customers. The ANT platform provides a user-friendly graphical interface, a robust test execution engine, and an automated backend to simplify test execution and validation of networks. It acts as an orchestrator, seamlessly integrating with multiple external industry traffic generation tools.

Manish Mangal, President and Head – Americas Communication Business, Tech Mahindra, said, "Networks have become the invisible lifeline of our digital society, every innovation, every human connection, every leap forward depends on them. In an era of unprecedented technological change, maintaining network reliability requires testing at equally unprecedented speed and scale. Integrating these AT&T applications enables us to reimagine network reliability in the AI-native era, providing global telecom operators with a highly automated solution for end-to-end network testing and certification."

The licensing agreement represents a significant milestone in an ongoing collaboration between Tech Mahindra and AT&T, showcasing their shared commitment to innovation in the telecommunications sector. A key component of this platform is the Open Tool, a versatile data and voice traffic simulation tool developed by AT&T. This tool is crucial for certifying and validating the functionality and connectivity of the mobile packet core network in both lab and production environments.

Kelly Marlar, Vice President and Managing Director of AT&T Intellectual Property, LLC , said, "This licensing agreement highlights AT&T's dedication to innovation and the value of our technology development. Licensing relationships like the one with Tech Mahindra transform our investments into new growth opportunities for AT&T, our licensees, and the industry. By working closely with trusted third parties, AT&T Intellectual Property helps accelerate innovation, drive new revenue streams, and bring proven solutions to market faster. This agreement is a strong example of how our technology licensing program is open for business, and we look forward to collaborating with more companies to deliver value and advance the industry together."

As part of this agreement, Tech Mahindra will now offer this proven solution to wireless providers in global markets where AT&T does not operate. This license aligns with Tech Mahindra's focus on enhancing and scaling customer service for global telecom providers with advanced telecommunication technologies. With a strong presence in the telecom industry and over 250 customers across 90 countries, Tech Mahindra is a trusted transformation partner with leading capabilities in network engineering and simplifying customer experience.

Logo: https://mma.prnewswire.com/media/2804444/Tech_Mahindra_New_Logo.jpg

SOURCE Tech Mahindra

Châtillon, France, November 11, 2025

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that the last patient visit has been completed in the Company’s Phase 3 VITESSE clinical trial of the VIASKIN® Peanut patch in peanut allergic children aged 4-7 years.

With the completion of the double-blind, placebo-controlled treatment phase of the study, DBV remains on track to announce topline data from VITESSE in the fourth quarter of this year.

“Last patient last visit represents a very important milestone for DBV, as it brings us one step closer to the potential of bringing this treatment option to peanut allergic children, their physicians and caregivers, if approved,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. “We’re grateful to the investigators, internal teams, and most importantly patients and caregivers for their time and commitment to this study. We look forward to sharing topline results this quarter.”

The VITESSE Phase 3 trial in peanut-allergic children ages 4 – 7 is a 12-month study evaluating the efficacy and safety of the VIASKIN® Peanut patch in 654 subjects (randomized 2:1), representing individuals across 86 sites in the U.S., Canada, Europe, the UK, and Australia. VITESSE is currently the largest treatment intervention study in peanut allergy.

About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements
This press release may contain forward-looking statements and estimates, including statements regarding the therapeutic potential of VIASKIN® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, plans and expectations regarding initiation of the confirmatory study, plans and expectations with respect to the submission of BLAs to FDA, anticipated support for the BLA submission, , and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the French Autorité des Marchés Financiers (“AMF”), DBV’s filings and reports with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, and future filings and reports made with the AMF and SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Katie Matthews
DBV Technologies
[email protected]

Media Contact
Brett Whelan
DBV Technologies
[email protected]

Version PDF

SummaryAlphabet delivered a stellar Q3, beating top- and bottom-line estimates, with Search and Cloud segments showing robust double-digit growth.GOOGL's advancements in AI, including Gemini and ad tools, are driving revenue growth and justifying increased capex to build out AI infrastructure.My LSTM neural network model projects a 20% upside to a $349 price target, supporting a continued BUY rating despite overbought technicals.Every pullback should be viewed as a buying opportunity, as GOOGL remains a must-have for long-term investors amid ongoing AI-driven momentum. Delmaine Donson/E+ via Getty Images

Investment Thesis The last time I wrote about Alphabet (GOOGL), in July 2025, I analysed the company’s Q2 earnings report and examined the key takeaways from the quarter and their implications for investors. I

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in GOOGL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I/we have a beneficial Long position in the shares of META, AMZN either through stock ownership, options, or other derivatives.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Quick Links:

By

:

Published: Nov 12, 2025, 03:34 GMT+00:00

Gold and silver extended their gains as safe-haven demand increased amid expectations of a Fed rate cut, weak U.S. data, and bullish chart setups.

Gold (XAU) price increased on Tuesday, reaching its highest level since October 23. This rally was driven by investor expectations that the Federal Reserve may cut interest rates in December.

Additionally, weak jobs data and a historic decline in consumer sentiment have further fueled the rally. The chart below shows that the US consumer sentiment has dropped to 50.3, which is the historical level.

The gold price tends to strengthen when interest rates drop. According to the FedWatch Tool, there is a 67.9% probability of a rate cut in December, which could continue to support demand for gold.

On the other hand, the U.S. dollar weakened as political uncertainty eased following a deal to end the government shutdown. The resumption of key economic data releases may confirm a softening economy. This increases the likelihood of Fed easing, an outcome that typically weighs on the dollar. While Fed officials remain cautious, voices like those of Governor Stephen Miran now suggest that a 50-basis-point cut could be on the table.

Moreover, safe-haven demand continues to support gold and silver (XAG). UBS expects gold demand to reach its highest levels since 2011. Any renewed political or financial volatility could drive gold toward $5,000 per ounce.

Similarly, other precious metals also gained this week, with silver approaching new record levels after forming strong support around the $45 region. Platinum (XPL) and palladium (XPD) also posted notable advances during the week. The combination of macroeconomic uncertainty and growing speculation over rate cuts continues to lift precious metals across the board.

Gold Technical Analysis
The weekly chart for spot gold shows that the price has been trading within an ascending channel. However, the surge in Q3 2025 pushed prices above the extension of this channel near the $4,400 region.

After this extended move, a strong correction followed, forming a bottom around the $3,900 support and initiating a solid rebound. In the short term, the price is now challenging the key $4,150 level, and a breakout above this level is required to push prices higher.

Since gold remains within a well-defined ascending channel, the overall trend is strongly bullish. Moreover, the ongoing economic and geopolitical crises may push gold to new highs heading into next year.

The 4-hour chart for spot gold shows that the price formed a strong bottom above $3,900 and broke out above the $4,030 level. Following this breakout, the price advanced into the resistance zone, reaching the lower boundary of that zone around $4,150. After hitting this resistance, gold is now consolidating as it searches for its next directional move.

As long as the price holds above $4,030, the short-term bias remains bullish. However, a clear breakout above the $4,150–$4,200 region is necessary to trigger a further rally toward the $4,400 level.

Overall, the current consolidation is a healthy development. The pause below $4,400 is constructive and suggests that the market is stabilising before a potential breakout.

Silver Technical Analysis
The daily chart for spot silver shows that the price remains in a strong short-term bullish trend. It rebounded from the key support level at $45, which aligns with the 50-day SMA. This rebound also led to a breakout above the critical $49.30 level, pushing prices to a higher level.

A breakout above the $54 level would confirm a strong bullish signal and could initiate a decisive upward move. The formation of an inverted head and shoulders pattern in Q3 2024, followed by an Adam and Eve pattern in Q1 2025, has established a solid base structure. This suggests that silver is likely to maintain its bullish momentum over the coming months.

Additionally, silver is now testing the key long-term resistance at $50-$55. A decisive breakout above this zone is expected to trigger a strong rally. The RSI is also rebounding from mid-levels, indicating strengthening bullish momentum. A sustained break above $54.50 would likely extend the rally toward the $60 level.

The 4-hour chart for spot silver shows that the price has formed an inverted head and shoulders pattern, with the neckline at the $49.30 level. A breakout above this neckline has triggered a gradual move higher. However, the price is currently consolidating around the $51.40 level, signalling some uncertainty before the next move.

A breakout above $52.60 would suggest that silver is likely to challenge new record highs. On the other hand, a drop back below $49.30 would keep the market in a consolidation phase.

Related Articles

Gold (XAU/USD) Price Forecast: $4,149 Tests Dual Channel Resistance – Breakout Above $4,161 KeyNatural Gas Price Forecast: $4.58 New High Clears 161.8% ABCD – Eyes $4.82Crude Oil Price Forecast: Bull Flag Breakout Reclaims 10-Day MA – Targets $64.55About the Author

Muhammad Umair is a finance MBA and engineering PhD. As a seasoned financial analyst specializing in currencies and precious metals, he combines his multidisciplinary academic background to deliver a data-driven, contrarian perspective. As founder of Gold Predictors, he leads a team providing advanced market analytics, quantitative research, and refined precious metals trading strategies.

Editors’ Picks

NASDAQ Index, SP500, Dow Jones Forecasts – Stocks Gain Ground As Traders Bet The Shutdown Will End Soon

Gold (XAU/USD) Price Forecast: $4,149 Tests Dual Channel Resistance – Breakout Above $4,161 Key

XRP News Today: Canary ETF Launch Nears as Traders Lock In Profits

Japanese Yen Forecast: USD/JPY Gains as Senate Vote Boosts Risk

US Dollar Forecast: DXY Slips Below 99.463 Pivot as Weak Jobs Data Hits Sentiment

Advertisement

-

NEW YORK--(BUSINESS WIRE)--Investcorp Credit Management BDC, Inc. (NASDAQ:ICMB) (“ICMB” or “Company”) today announced that it will release its financial results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025, after the close of the financial markets.

The Company will host an earnings conference call at 11:00 am (Eastern Time) on Thursday, November 13, 2025 to review its financial results and conduct a question-and-answer session. All interested parties may participate in the conference call by dialing (800) 550-9893 5-10 minutes prior to the call; international callers should dial (858) 609-8959. Participants should enter 872058# as the passcode, then press 2 when prompted. For those who are not able to listen to the call, a replay will be available shortly after the call by visiting our website at http://icmbdc.com/earnings-calls/.

About Investcorp Credit Management BDC, Inc.

The Company is an externally-managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company under the Investment Company Act of 1940. The Company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing in debt and related equity investments of privately held middle-market companies. The Company seeks to invest primarily in middle-market companies that have annual revenues of at least $50 million and earnings before interest, taxes, depreciation, and amortization of at least $15 million. The Company's investment activities are managed by its investment adviser, CM Investment Partners LLC. To learn more about Investcorp Credit Management BDC, Inc., please visit www.icmbdc.com.

Forward-Looking Statements

Statements included herein or on the conference call may contain "forward-looking statements," which relate to future performance or ICMB’s financial condition, are based upon current expectations and are inherently uncertain. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of assumptions, risks and uncertainties and other factors, some of which are beyond the Company’s control, including the impact of significant market volatility on the Company’s business, its portfolio companies, its industry and the global economy. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein, except as required by law. All forward-looking statements speak only as of the date of this press release.

More News From Investcorp Credit Management BDC

Back to Newsroom

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ABBV over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Alector issued a press release on October 21, 2025, "announc[ing] results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN)." According to the Company, its drug candidate "did not meet the clinical co-primary endpoint of slowing FTD-GRN progression," and "the secondary and exploratory endpoints, such as fluid biomarkers and volumetric magnetic resonance imaging (vMRI), demonstrated no treatment-related effects on FTD-GRN." Based on this news, shares of Alector fell by almost 50% on the next day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

NEW YORK and NEW ORLEANS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 8, 2025 to file lead plaintiff applications in a securities class action lawsuit against Marex Group plc (“Marex” or the “Company”) (NasdaqGS: MRX), if they purchased or otherwise acquired the Company’s securities between May 16, 2024 and August 5, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of Marex and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-mrx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 8, 2025.

About the Lawsuit

Marex and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 5, 2025, NINGI Research reported numerous allegations about the Company including, among other things, that it “has engaged in a multi-year accounting scheme involving a web of opaque off-balance-sheet entities, fictitious intercompany transactions, and misleading disclosures to conceal significant losses, inflate profits, and mask its true risk exposure” and that it has “numerous multi-million-dollar discrepancies in intercompany receivables and loans across Marex’s sprawling network of 56+ entities.” The report further identified “a $17 million receivable created out of thin air, a subsidiary whose reported profit was inflated by 150% in group filings before being liquidated, and an asset valued at $14.9 million that was sold to Robinhood for just $2.5 million weeks later, with no reported loss” and that the Company concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund it both controls and trades with, and that it is using the fund to generate non-cash trading profits and inflate operating cash flow by misclassifying structured note issuance as income.

On this news, the price of Marex’s shares fell $2.33, or 6.2%, to close at $35.31 per share on August 5, 2025, on unusually heavy trading volume.

The case is Narayanan v. Marex Group PLC, et al., No. 25-cv-08393.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected] 
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK and NEW ORLEANS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until December 30, 2025 to file lead plaintiff applications in a securities class action lawsuit against Synopsys, Inc. (“Synopsys” or the “Company”) (NasdaqGS: SNPS), if they purchased or otherwise acquired the Company’s securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased securities of Synopsys and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-snps/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 30, 2025.

About the Lawsuit

Synopsys and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On September 9, 2025, post-market, the Company announced its 3Q2025 financial results, disclosing quarterly revenue of $1.740 billion, missing its prior guidance of between $1.755 billion and $1.785 billion, and reported net income of $242.5 million, a 43% year-over-year decline from $425.9 million reported for 3Q 024. Further, the Company reported that its Design IP segment accounted for approximately 25% of revenue and came in at $426.6 million, a 7.7% decline year-over-year, and also provided guidance inferring that Design IP revenues will decline by at least 5% on a full-year basis in fiscal 2025.

On this news, the price of Synopsys’ shares fell $216.59, or 35.8%, to close at $387.78 per share on September 10, 2025, on unusually heavy trading volume.

The case is Kim v. Synopsis, Inc., et al., Case No. 25-cv-09410.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

NEW YORK CITY and NEW ORLEANS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 23, 2025 to file lead plaintiff applications in a securities class action lawsuit against James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX), if they purchased or otherwise acquired the Company’s shares between May 20, 2025, and August 18, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

What You May Do

If you purchased shares of James Hardie and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-jhx/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by December 23, 2025.

About the Lawsuit

James Hardie and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On August 19, 2025, despite prior reassurances that its North America Fiber Cement segment remained strong, the Company disclosed that sales in North America Fiber Cement declined by 12% due to customer destocking first discovered “in April through May,” that was expected to impact sales for at least the next two quarters.

On this news, the price of James Hardie’s shares fell by over 34%, or $9.79 per share, from a closing price of $28.43 per share on August 18, 2025 to $18.64 per share on August 20, 2025.

The case is Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 25-cv-13018.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC

Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

November 11, 2025 22:53 ET

 | Source:

TH International Limited

SHANGHAI and NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive operator of Tim Hortons coffee shops in China, plans to release its third quarter financial results before the U.S. market opens on Tuesday, December 9, 2025, with a conference call to follow at 8:00 AM EST or 9:00 PM China Standard Time. The conference call will be webcast, and can be accessed on the company Investor Relations website at https://ir.timschina.com/events-presentations/presentations-webcasts.

Participants are kindly encouraged to pre-register for the conference call, by using the link provided below.

Pre-registration Link:

https://register-conf.media-server.com/register/BId10b556eeb90481aa578a2eaa12a8b1e

ABOUT TH INTERNATIONAL LIMITED

TH International Limited (Nasdaq: THCH) (“Tims China”) is the parent company of the exclusive master franchisees of Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Tims China was founded by Cartesian Capital Group and Tim Hortons Restaurants International, a subsidiary of Restaurant Brands International (TSX: QSR) (NYSE: QSR).

The company’s philosophy is rooted in world-class execution and data-driven decision making and centered around true local relevance, continuous innovation, genuine community, and absolute convenience. For more information, please visit https://www.timschina.com.

Contacts

Investor Relations
[email protected] or [email protected]

Public Relations
[email protected]

Follow @TimHortonsChina

SINGAPORE, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The Government of the Philippines, through the Bureau of Fisheries and Aquatic Resources (BFAR) and the Philippine Crop Insurance Corporation (PCIC), has partnered with global conservation organization Rare and Willis, a WTW business (NASDAQ: WTW), to launch the country’s first parametric insurance solution for small-scale fishers.

This project has been developed through support from the Ocean Risk and Resilience Action Alliance (ORRAA) with funding from the Government of Canada and the UK Government’s Blue Planet Fund.

The partnership is aimed at protecting the livelihoods of 14,200 small-scale fishers, across 24 coastal municipalities in the Philippines through parametric insurance, designed to mitigate income losses resulting from adverse weather conditions that prevent safe fishing in nearshore waters. With changing weather patterns, protecting the livelihoods of small-scale fishers is a national priority for the Government of the Philippines; to expand livelihood protections, BFAR is piloting this coverage as a benefit to fisher registration.

BFAR will serve as the policyholder for the pilot, offering parametric insurance coverage to small-scale fishers as a benefit for fisher registration and commitment to sustainable fishing practices. It has allocated a portion of its budget to fund the premium costs for this pilot, demonstrating strong government support for innovative approaches to climate risk. The coverage will provide up to US$100 per policy cycle to help offset income loss from dangerous weather. “This is not just insurance, it is an investment in our fishers,” said Roy Ortega of BFAR, who also leads the Technical Working Group on Parametric Insurance. “We’re protecting those who protect our seas.”

Dr Christopher Au, Head of APAC Climate Risk Centre, at Willis, said: “With over 1.9 million registered small-scale fishers relying on the nearshore for their livelihoods, the impacts of climate change, such as high winds, rough seas and heavy rainfall, pose increasing risks to their safety and income. The new insurance solution, the first of its kind in the Philippines, uses a weather index based on wind speed, sea state and rainfall to determine payout eligibility, ensuring timely and direct compensation to fishers when fishing days are lost.”

The parametric risk transfer capacity is provided by The Natural Disaster Fund, a public-private partnership between the UK and German Governments and supported by Hannover Re and managed by the team from Global Parametrics Limited (a subsidiary of CelsiusPro Group specializing in parametric protection against climate and natural disaster risks). Designed to be affordable and scalable, it will offer timely and predictable financial support to fishers when weather conditions are unfavorable. The solution utilizes a parametric index that is calculated over five-day periods and compared against historical data to determine the ‘severity’ of the weather relative to expected conditions. Insurance coverage will be provided to fishers who formally register and commit to sustainable fishing practices.

“Bad weather can cause serious hardship for fishing households throughout the tropics. This pilot takes a proven product - parametric insurance - and applies it to a new context, insuring people rather than assets. The result will be less financial pressure on households, less fishing pressure on ecosystems, and more resilient coastal communities,” said Brett Jenks, CEO of Rare.

“As climate change intensifies and weather patterns become increasingly unpredictable, small-scale fishers face mounting risks to their safety and livelihoods," said Chip Cunliffe, Senior Director of Innovation and Pipeline Development at ORRAA. "This partnership represents a vital step in building market-ready solutions that deliver innovative financial solutions like parametric insurance to help protect income and build the resilience of climate vulnerable coastal communities in the Philippines."

“This is an important first for PCIC as we explore revenue-based parametric insurance for fishers,” said Israel Q. De La Cruz, Department Manager at PCIC, who is directly involved in the pilot. “We see this as a complement to our existing coverage, offering a faster, data-triggered option that can respond when fishers are unable to go to sea. If the pilot proves successful, we are hopeful it can evolve into a nationally scalable tool for protecting coastal livelihoods.”

About Rare

Rare is an international conservation organization inspiring change so people and nature thrive. Rare’s people-centered approach, rooted in behavioral science and design thinking, inspires shifts in behaviors and practices that measurably benefit people and nature. With 50 years of experience on the frontlines of conservation, Rare facilitates and empowers community-driven solutions that help people manage their futures.

About ORRAA

The Ocean Risk and Resilience Action Alliance (ORRAA) is the only multi-sector collaboration connecting the finance and insurance sectors, governments, multilateral organisations, civil society, and local partners, to pioneer finance and insurance products that incentivise investment into coastal and ocean resilience, and through Nature-based Solutions.

The mission, by 2030, is to activate at least USD$500 million of investment to build the resilience of 250 million climate vulnerable coastal people in the Global South.

ORRAA is delivering system-wide change by growing an investable product pipeline and generating the transformative investment instruments, vehicles and policies that contribute to a regenerative and sustainable blue economy. These solutions enable coastal communities and the Ocean to adapt and thrive, creating greater economic, social and cultural resilience.

This project was supported by the Ocean Risk and Resilience Action Alliance through funding from the Government of Canada, through Environment and Climate Change Canada, and the UK Government, through the Department for Environment, Food and Rural Affairs.

Ce projet a été soutenu par Ocean Risk and Resilience Action Alliance grâce aux financements du Gouvernement du Canada, via Environnement et Changement climatique Canada, et du Gouvernement du Royaume-Uni, via le ministère de l’Environnement, de l’Alimentation et des Affaires rurales.

About WTW

At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance.

Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at wtwco.com.

Media contact

Clara Goh: +65 6958 2542
[email protected]

Zach Lowe: +1 202 577 8125
[email protected]

[email protected]

WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (such offering, the “Equity Offering”) and its underwritten public offering of $200.0 million aggregate principal amount of its 1.625% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”). The Equity Offering was upsized from the previously announced offering size of $200.0 million of shares of common stock.

Cogent estimates that the net proceeds from the Equity Offering and the Convertible Notes Offering will be approximately $475.3 million, after deducting underwriting discounts and commissions and Cogent’s estimated offering expenses. In addition, Cogent has granted the underwriters of the Equity Offering a 30-day option to purchase up to an additional 1,451,613 shares of its common stock, on the same terms and conditions, and granted the underwriters of the Convertible Notes Offering a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Convertible Notes, solely to cover over-allotments in the Convertible Notes Offering, on the same terms and conditions.

The Equity Offering is expected to close on November 13, 2025, while the Convertible Notes Offering is expected to close on November 18, 2025, in each case, subject to satisfaction of customary closing conditions. The closing of neither the Equity Offering nor the Convertible Notes Offering is conditioned upon the closing of the other offering.

The Convertible Notes will be general, unsecured, senior obligations of Cogent. The Convertible Notes will accrue interest payable semi-annually in arrears on May 15 and November 15 of each year, beginning on May 15, 2026, at a rate equal to 1.625% per year. The Convertible Notes will mature on November 15, 2031, unless earlier converted, redeemed or repurchased by Cogent.

Before August 15, 2031, noteholders may convert their Convertible Notes at their option only in certain circumstances. At any time from, and including, August 15, 2031 until the close of business on the scheduled trading day immediately before the maturity date, the Convertible Notes will be convertible at the option of the holders. Cogent will settle conversions by paying or delivering, as applicable, cash, shares of its shares of its common stock, or a combination of cash and shares of its common stock, at Cogent’s election. The initial conversion rate is 22.2469 shares of its common stock, per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $44.95 per share of common stock and represents a conversion premium of approximately 45.0% above the public offering price per share of common stock in the Equity Offering. If a “make-whole fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then Cogent will in certain circumstances increase the conversion rate for a specified period of time.

The Convertible Notes will be redeemable, in whole or in part (subject to certain limitations), at Cogent’s option at any time, and from time to time, on a redemption date on or after November 20, 2029 and on or before the 26th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price per share of the common stock exceeds 130% of the conversion price for the Convertible Notes on (1) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date Cogent sends the related redemption notice; and (2) the trading day immediately before the date Cogent sends such notice.

If a “fundamental change” (as defined in the indenture that will govern the Convertible Notes) occurs, then, subject to certain exceptions, noteholders may require Cogent to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date.

Cogent intends to use the net proceeds from the Equity Offering and the Convertible Notes Offering to repay $50 million of loans outstanding under its existing term loan facility, plus accrued interest and associated fees, and the remainder for development and regulatory activities relating to bezuclastinib and other product candidates, the anticipated commercial launch and commercialization of bezuclastinib, as well as for working capital and general corporate purposes.

J.P. Morgan, Jefferies, Leerink Partners and Guggenheim Securities are acting as joint-book running managers for the Equity Offering. LifeSci Capital is acting as lead manager and Raymond James is acting as co-manager for the Equity Offering.

Jefferies and J.P. Morgan are acting as joint book-running managers for the Convertible Notes Offering.

The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-291384), which was filed with the Securities and Exchange Commission (“SEC”) on November 7, 2025 and automatically became effective upon filing.

Preliminary prospectus supplements and the accompanying base prospectuses relating to and describing the terms of each offering were filed with the SEC on November 10, 2025 and are expected to be available on the SEC’s website on November 12, 2025. Final prospectus supplements and the accompanying base prospectuses relating to and describing the terms of each offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offerings can be made only by means of prospectus supplements and accompanying base prospectuses, copies of which may each be obtained at the SEC’s website at www.sec.gov, or by request to Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at [email protected].

About Cogent Biosciences, Inc.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. Cogent also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2/3, ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and completion of the offerings, the satisfaction of customary closing conditions with respect to the offerings, and the anticipated use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to: our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the offerings; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offerings; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on November 7, 2025 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025, and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplements related to the offerings. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Contact:

Christi Waarich
Senior Director, Investor Relations
[email protected]
617-830-1653

Analyst’s Disclosure:I/we have a beneficial long position in the shares of UPWK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Not intended as investment advice. Author's opinion only. Write-up may contain errors/inaccuracies and will not be updated. Seek professional advice before any investment or tax decision.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Eli Lilly is dropping CVS Health's drug benefit plan for its employees after CVS stopped covering its weight-loss drug in favor of a rival medication from Novo Nordisk , Bloomberg News reported on Tuesday, citing people familiar with the matter.

BROADVIEW, Ill., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH” or the “Company”), a national seller of gourmet specialty foods, today announced the timing for a call with investors to discuss third quarter 2025 financial results.

The Company will publish its Third Quarter 2025 financial results on Friday, November 14, 2025 and host an investor conference call on Monday, November 17, 2025 at 4:00 PM Eastern Time to discuss results for the quarter ended September 30, 2025. Interested participants may join the call online or by phone using the access information below. A Q&A segment will follow the prepared remarks, addressing questions submitted in advance. To submit question, email [email protected] with the subject “Q3 Earnings Q&A” by Sunday, November 16, 2025, 12:00 PM Eastern Time.

Join Zoom Meeting
https://us04web.zoom.us/j/76954915974?pwd=XBcT5IldWJ3yl8Bd65JN9hmyC1qetb.1
Meeting ID: 769 5491 5974
Passcode: 723819
One tap mobile +13017158592, 76954915974# US

About Innovative Food Holdings, Inc.
At IVFH, we help make meals special. We provide access to foods that are hard to find, have a compelling story, or are on the forefront of food trends. Our gourmet foods marketplace connects the world’s best artisan food makers with top professional chefs nationwide. We curate the assortment, experience, and tech enabled tools that help our professional chefs create unforgettable experiences for their guests. Additional information is available at www.ivfh.com.

Forward-Looking Statements

This release contains certain forward-looking statements and information relating to the Company that are based on the current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, the Company. Such statements, including those related to the Company’s growth plans, reflect the current views of the Company with respect to future events and are subject to certain assumptions, including those described in this release. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein, which include words such as “should,” “could,” “will,” “anticipate,” “believe,” “intend,” “plan,” “might,” “potentially,” “targeting,” “expect,” or similar expressions. Additional factors that could also cause actual results to differ materially relate to current conditions and expected future developments, international crises, environmental and economic issues and other risk factors described in the Company’s public filings. As a result, readers are cautioned not to place undue reliance on these forward-looking statements and should understand that these statements are not guarantees of performance or results and that there are a number of risks, uncertainties and other important factors, many of which are beyond the Company’s control, that could cause the Company’s actual results to differ materially from those expressed in these statements, including, among others: economic factors affecting consumer confidence and discretionary spending; cost inflation/deflation and commodity volatility; competition; reliance on third party suppliers and interruption of product supply or increases in product costs; changes in the Company’s relationships with vendors and customers. The Company does not intend to update these forward-looking statements.

For a detailed discussion of these risks, uncertainties and other factors that could cause the Company’s actual results to differ materially from those anticipated or expressed in any forward-looking statements, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”). Additional risks and uncertainties are discussed from time to time in current, quarterly and annual reports filed by the Company with the SEC, which are available on the SEC’s website at https://www.sec.gov/.

Investor and Media contact:
Gary Schubert
Chief Executive Officer
Innovative Food Holdings, inc.
[email protected]